Open AccessEvaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption
Author(s) -
MarieAngélique De Scheerder,
Clarissa Van Hecke,
Henrik Zetterberg,
Dietmar Fuchs,
Nele De Langhe,
Sofie Rutsaert,
Bram Vrancken,
Wim Trypsteen,
Ytse Noppe,
Beatrijs Van Der Gucht,
Jolanda Pelgrom,
Filip Van Wanzeele,
Sarah Palmer,
Philippe Lemey,
Magnus Gisslén,
Linos Vandekerckhove
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa003
Subject(s) - viral load , neopterin , biomarker , medicine , kynurenine , immune system , immunology , neuroinflammation , kynurenine pathway , inflammation , biology , virology , virus , tryptophan , biochemistry , amino acid
Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants. Little is known about the safety of ATI and its long-term impact on patient health.